CAR22-41BB-CD3z-tEGFR-T cells

CAR22-41BB-CD3z-tEGFR-T cells are a form of autologous chimeric antigen receptor (CAR) T cell therapy engineered to target the CD22 antigen, commonly expressed in B-cell malignancies such as B-cell acute lymphoblastic leukemia (B-ALL). These T cells are genetically modified to express a CAR composed of a CD22-specific single-chain variable fragment (scFv) linked to intracellular signaling domains from 4-1BB (CD137) and CD3-zeta (CD3ζ), providing activation and co-stimulatory signals for T cell proliferation, survival, and cytotoxic function. The construct additionally includes a truncated epidermal growth factor receptor (tEGFR) that serves as a safety/suicide marker, allowing elimination of the infused cells via cetuximab if needed for toxicity control[1][6][7]. The therapy is developed for use in relapsed or refractory B-ALL and possibly other CD22-positive B-cell malignancies, especially after failure of prior CD19-targeted therapies. The primary mechanism is immunological targeting and lysis of CD22-positive cancer cells through redirected T cell cytotoxicity.

Other names

CAR22-41BB-CD3ζ-tEGFR-T cellsCD22-CAR-T cells with 4-1BB and CD3zetaCD-22-CAR-T cells with 4-1BB and CD3zetaCD 22-CAR-T cells with 4-1BB and CD3zetahumanized CAR22-41BB-CD3ζ-tEGFR-T cells